AVO Stock Overview
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer.
Advanced Oncotherapy Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.23|
|52 Week High||UK£0.40|
|52 Week Low||UK£0.20|
|1 Month Change||9.52%|
|3 Month Change||9.52%|
|1 Year Change||-36.99%|
|3 Year Change||-42.50%|
|5 Year Change||-41.03%|
|Change since IPO||-97.29%|
Recent News & Updates
Is Advanced Oncotherapy plc (LON:AVO) Potentially Undervalued?
Advanced Oncotherapy plc ( LON:AVO ), might not be a large cap stock, but it saw a significant share price rise of over...
|AVO||GB Medical Equipment||GB Market|
Return vs Industry: AVO underperformed the UK Medical Equipment industry which returned -19.9% over the past year.
Return vs Market: AVO underperformed the UK Market which returned -14.4% over the past year.
|AVO Average Weekly Movement||5.4%|
|Medical Equipment Industry Average Movement||5.8%|
|Market Average Movement||5.5%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.9%|
Stable Share Price: AVO is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AVO's weekly volatility (5%) has been stable over the past year.
About the Company
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties.
Advanced Oncotherapy Fundamentals Summary
|AVO fundamental statistics|
Is AVO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVO income statement (TTM)|
|Cost of Revenue||UK£0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.064|
|Net Profit Margin||0.00%|
How did AVO perform over the long term?See historical performance and comparison
Is AVO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AVO?
Other financial metrics that can be useful for relative valuation.
|What is AVO's n/a Ratio?|
Price to Book Ratio vs Peers
How does AVO's PB Ratio compare to its peers?
|AVO PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
CREO Creo Medical
POLX Polarean Imaging
EKF EKF Diagnostics Holdings
AVO Advanced Oncotherapy
Price-To-Book vs Peers: AVO is good value based on its Price-To-Book Ratio (1.9x) compared to the peer average (3.4x).
Price to Earnings Ratio vs Industry
How does AVO's PE Ratio compare vs other companies in the GB Medical Equipment Industry?
Price-To-Book vs Industry: AVO is expensive based on its Price-To-Book Ratio (1.9x) compared to the UK Medical Equipment industry average (1.9x)
Price to Book Ratio vs Fair Ratio
What is AVO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.9x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate AVO's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AVO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AVO (£0.23) is trading above our estimate of fair value (£0.19)
Significantly Below Fair Value: AVO is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Advanced Oncotherapy forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).
Earnings vs Market: AVO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AVO is expected to become profitable in the next 3 years.
Revenue vs Market: AVO's revenue (54.4% per year) is forecast to grow faster than the UK market (4.4% per year).
High Growth Revenue: AVO's revenue (54.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Advanced Oncotherapy performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVO is currently unprofitable.
Growing Profit Margin: AVO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVO is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare AVO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-26.3%).
Return on Equity
High ROE: AVO has a negative Return on Equity (-53.87%), as it is currently unprofitable.
Discover strong past performing companies
How is Advanced Oncotherapy's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AVO's short term assets (£32.8M) exceed its short term liabilities (£26.0M).
Long Term Liabilities: AVO's short term assets (£32.8M) do not cover its long term liabilities (£66.7M).
Debt to Equity History and Analysis
Debt Level: AVO's net debt to equity ratio (35.5%) is considered satisfactory.
Reducing Debt: AVO's debt to equity ratio has increased from 21% to 39.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AVO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.3% each year
Discover healthy companies
What is Advanced Oncotherapy current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Advanced Oncotherapy Dividend Yield vs Market|
|Company (Advanced Oncotherapy)||n/a|
|Market Bottom 25% (GB)||2.1%|
|Market Top 25% (GB)||6.0%|
|Industry Average (Medical Equipment)||2.8%|
|Analyst forecast in 3 Years (Advanced Oncotherapy)||n/a|
Notable Dividend: Unable to evaluate AVO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AVO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Nicolas Serandour has been the Chief Executive Officer of Advanced Oncotherapy Plc since October 27, 2016. Mr. Serandour served as the Chief Financial Officer and Chief Operating Officer at Advanced On...
CEO Compensation Analysis
|Nicolas Serandour's Compensation vs Advanced Oncotherapy Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||UK£503k||UK£300k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||UK£336k||UK£300k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||UK£401k||UK£247k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||UK£1m||UK£233k|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||UK£239k||UK£215k|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||UK£208k||UK£180k|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||UK£343k||UK£165k|
Compensation vs Market: Nicolas's total compensation ($USD575.26K) is above average for companies of similar size in the UK market ($USD339.71K).
Compensation vs Earnings: Nicolas's compensation has increased whilst the company is unprofitable.
Experienced Management: AVO's management team is seasoned and experienced (7.3 years average tenure).
Experienced Board: AVO's board of directors are considered experienced (7.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|02 Mar 22||BuyUK£26,500||Enrico Vanni||Individual||100,000||UK£0.27|
|02 Mar 22||BuyUK£27,925||Michael Sinclair||Individual||100,000||UK£0.28|
|02 Mar 22||BuyUK£38,700||Stephen Myers||Individual||140,000||UK£0.28|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Advanced Oncotherapy plc's employee growth, exchange listings and data sources
- Name: Advanced Oncotherapy plc
- Ticker: AVO
- Exchange: AIM
- Founded: 1994
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: UK£116.663m
- Shares outstanding: 507.23m
- Website: https://www.avoplc.com
Number of Employees
- Advanced Oncotherapy plc
- 4 Tenterden Street
- Third Floor
- Greater London
- W1S 1TE
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AVO||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Aug 2006|
|R3I1||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Aug 2006|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/04 00:00|
|End of Day Share Price||2022/10/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.